Antibacterial treatment strategies in hospitalized patients: What role for pharmacoeconomics?

Article Type
Changed
Tue, 09/25/2018 - 14:59
Display Headline
Antibacterial treatment strategies in hospitalized patients: What role for pharmacoeconomics?
Article PDF
Author and Disclosure Information

Morton P. Goldman, PharmD, BCPS
Director, Pharmacotherapy Services, Department of Pharmacy, Cleveland Clinic, Cleveland, OH

Radhika Nair, PhD
Health Sciences Researcher, Abbott Laboratories, Austin, TX*

Correspondence: Morton P. Goldman, PharmD, BCPS, Department of Pharmacy, QQb5, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; goldmam@ccf.org

*At the time this article was written, Dr. Nair was Outcomes Research Specialist, Department of Pharmacy, Cleveland Clinic, Cleveland, OH.

Dr. Goldman reported that he has received fees for serving on speakers’ bureaus for Enzon Pharmaceuticals, Wyeth Pharmaceuticals, Abbott Laboratories, Schering-Plough Corp., Forest Laboratories, and Pfizer Inc., and that he has received honoraria for writing from Wyeth.

Dr. Nair reported that she receives a salary from Abbott Laboratories (her current employer) and that she has received honoraria for writing from Wyeth.

The authors reported that they prepared this article without assistance from any medical education company.

Publications
Page Number
S38-S47
Author and Disclosure Information

Morton P. Goldman, PharmD, BCPS
Director, Pharmacotherapy Services, Department of Pharmacy, Cleveland Clinic, Cleveland, OH

Radhika Nair, PhD
Health Sciences Researcher, Abbott Laboratories, Austin, TX*

Correspondence: Morton P. Goldman, PharmD, BCPS, Department of Pharmacy, QQb5, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; goldmam@ccf.org

*At the time this article was written, Dr. Nair was Outcomes Research Specialist, Department of Pharmacy, Cleveland Clinic, Cleveland, OH.

Dr. Goldman reported that he has received fees for serving on speakers’ bureaus for Enzon Pharmaceuticals, Wyeth Pharmaceuticals, Abbott Laboratories, Schering-Plough Corp., Forest Laboratories, and Pfizer Inc., and that he has received honoraria for writing from Wyeth.

Dr. Nair reported that she receives a salary from Abbott Laboratories (her current employer) and that she has received honoraria for writing from Wyeth.

The authors reported that they prepared this article without assistance from any medical education company.

Author and Disclosure Information

Morton P. Goldman, PharmD, BCPS
Director, Pharmacotherapy Services, Department of Pharmacy, Cleveland Clinic, Cleveland, OH

Radhika Nair, PhD
Health Sciences Researcher, Abbott Laboratories, Austin, TX*

Correspondence: Morton P. Goldman, PharmD, BCPS, Department of Pharmacy, QQb5, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; goldmam@ccf.org

*At the time this article was written, Dr. Nair was Outcomes Research Specialist, Department of Pharmacy, Cleveland Clinic, Cleveland, OH.

Dr. Goldman reported that he has received fees for serving on speakers’ bureaus for Enzon Pharmaceuticals, Wyeth Pharmaceuticals, Abbott Laboratories, Schering-Plough Corp., Forest Laboratories, and Pfizer Inc., and that he has received honoraria for writing from Wyeth.

Dr. Nair reported that she receives a salary from Abbott Laboratories (her current employer) and that she has received honoraria for writing from Wyeth.

The authors reported that they prepared this article without assistance from any medical education company.

Article PDF
Article PDF
Related Articles
Page Number
S38-S47
Page Number
S38-S47
Publications
Publications
Article Type
Display Headline
Antibacterial treatment strategies in hospitalized patients: What role for pharmacoeconomics?
Display Headline
Antibacterial treatment strategies in hospitalized patients: What role for pharmacoeconomics?
Citation Override
Cleveland Clinic Journal of Medicine 2007 August;74(suppl 4):S38-S47
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media